Assessment |
Biopsychology |
Comparative |
Cognitive |
Developmental |
Language |
Individual differences |
Personality |
Philosophy |
Social |
Methods |
Statistics |
Clinical |
Educational |
Industrial |
Professional items |
World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
|
Iproniazid chemical structure | |
| N'-propan-2-ylpyridine-4-carbohydrazide IUPAC name | |
| CAS number 54-92-2 |
ATC code |
| PubChem 3748 |
DrugBank [1] |
| Chemical formula | {{{chemical_formula}}} |
| Molecular weight | 179.219 |
| Bioavailability | ? |
| Metabolism | ? |
| Elimination half-life | ? |
| Excretion | ? |
| Pregnancy category | ? |
| Legal status | ? |
| Routes of administration | ? |
Iproniazid (iproniazid phosphate, marketed under the names Marsilid®, Iprozid®, Ipronid®, Rivivol®, Propilniazida®) is a monamine oxidase inhibitor (MAOI) that was developed as the first anti-depressant. It was originally intended to treat tuberculosis when it was discovered that patients given iproniazid became "inappropriately happy," subsequently with further research iproniazid was marketed specifically for depression in 1958. It was later replaced by less hepatotoxic drugs.
See also[]
- Amine oxidase inhibitors
- Antidepressant drugs
- Antihypertensicve drugs
- Antitubercular drugs
- Monoamine oxidase inhibitors
| This page uses Creative Commons Licensed content from Wikipedia (view authors). |